Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 Dose Escalation of Stapokibart in Healthy Subjects
NCT06161090Phase 1Completed
- Sponsor
- Keymed Biosciences
- Start
- Sep 2019
- Primary completion
- Jan 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of stapokibart in atopic dermatitis (AD), asthma, chronic rhinosinusitis with nasal polyps (CRSwNP) and 1 more (5 arms), sponsored by Keymed Biosciences. Primary endpoint: Adverse event. Started Sep 2019; status: completed.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)asthmachronic rhinosinusitis with nasal polyps (CRSwNP)allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT06161090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06161090.